A trial treating 16 adult ALL patients with Cy 1.5 to 3.0 g/m2 as LD followed by an anti-CD19 CD28-CD3z was able to achieve an unprecedented complete response rate (CRR) of 78% (105). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.